RadNet Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

RadNet wird ein jährliches Gewinn- und Umsatzwachstum von 37% bzw. 7.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 34.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.6% betragen.

Wichtige Informationen

37.0%

Wachstumsrate der Gewinne

34.6%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	7.3%
Zukünftige Eigenkapitalrendite	5.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For RadNet, Inc. (NASDAQ:RDNT) Suggests It's 41% Undervalued

Nov 26

RadNet JV acquires Montclair Radiology's outpatient radiology assets

Oct 11

Some Investors May Be Worried About RadNet's (NASDAQ:RDNT) Returns On Capital

Oct 10

RadNet Presents With The Idiosyncratic Risk Premia To Deliver Risk-Adjusted Alpha

Aug 28

Here's Why RadNet (NASDAQ:RDNT) Has A Meaningful Debt Burden

Aug 12

RadNet Non-GAAP EPS of $0.15 beats by $0.06, revenue of $354.1M beats by $5.16M;reaffirms FY guidance

Aug 09

RadNet (NASDAQ:RDNT) Is Reinvesting At Lower Rates Of Return

Jul 01

Is It Time To Consider Buying RadNet, Inc. (NASDAQ:RDNT)?

Jun 17

Is RadNet (NASDAQ:RDNT) A Risky Investment?

May 11

Estimating The Intrinsic Value Of RadNet, Inc. (NASDAQ:RDNT)

Apr 06

Is RadNet (NASDAQ:RDNT) Using Too Much Debt?

Jan 24

Returns On Capital At RadNet (NASDAQ:RDNT) Have Stalled

Dec 23

Is RadNet, Inc. (NASDAQ:RDNT) Potentially Undervalued?

Dec 08

RadNet, Inc.'s (NASDAQ:RDNT) Intrinsic Value Is Potentially 35% Above Its Share Price

Nov 23

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:RDNT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,010	68	86	246	2
12/31/2025	1,913	58	70	233	5
12/31/2024	1,761	38	40	184	5
3/31/2024	1,658	21	27	205	N/A
12/31/2023	1,617	3	44	221	N/A
9/30/2023	1,580	4	28	186	N/A
6/30/2023	1,528	-13	39	181	N/A
3/31/2023	1,479	-13	39	178	N/A
12/31/2022	1,430	11	27	146	N/A
9/30/2022	1,382	8	-11	142	N/A
6/30/2022	1,365	23	-5	157	N/A
3/31/2022	1,344	18	-27	122	N/A
12/31/2021	1,324	25	6	149	N/A
9/30/2021	1,297	35	58	164	N/A
6/30/2021	1,256	24	77	161	N/A
3/31/2021	1,138	11	148	221	N/A
12/31/2020	1,098	-15	140	234	N/A
9/30/2020	1,090	-10	109	192	N/A
6/30/2020	1,091	-13	103	191	N/A
3/31/2020	1,164	2	26	118	N/A
12/31/2019	1,154	15	30	104	N/A
9/30/2019	1,111	33	34	111	N/A
6/30/2019	1,060	35	37	114	N/A
3/31/2019	1,015	36	38	119	N/A
12/31/2018	975	32	45	117	N/A
9/30/2018	953	-4	84	154	N/A
6/30/2018	939	-6	76	139	N/A
3/31/2018	925	-6	81	136	N/A
12/31/2017	922	0	N/A	142	N/A
9/30/2017	912	11	N/A	112	N/A
6/30/2017	909	9	N/A	90	N/A
3/31/2017	897	7	N/A	102	N/A
12/31/2016	885	7	N/A	92	N/A
9/30/2016	875	5	N/A	82	N/A
6/30/2016	859	11	N/A	91	N/A
3/31/2016	845	11	N/A	71	N/A
12/31/2015	810	8	N/A	67	N/A
9/30/2015	779	11	N/A	67	N/A
6/30/2015	755	7	N/A	69	N/A
3/31/2015	730	9	N/A	83	N/A
12/31/2014	718	1	N/A	61	N/A
9/30/2014	710	-2	N/A	58	N/A
6/30/2014	701	-7	N/A	57	N/A
3/31/2014	699	-9	N/A	46	N/A
12/31/2013	703	2	N/A	66	N/A
9/30/2013	684	53	N/A	62	N/A
6/30/2013	669	58	N/A	63	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RDNTDas prognostizierte Gewinnwachstum (37% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: RDNTDie Erträge des Unternehmens (37% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: RDNTEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: RDNTDie Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: RDNTDie Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RDNTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.6%).

RadNet Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.2% to US$57.17

Price target increased by 7.0% to US$53.33

Consensus EPS estimates increase by 12%

Price target increased by 12% to US$45.80

Radnet, Inc. Revises Earnings Guidance for the Year 2023

Consensus EPS estimates upgraded to US$0.10 loss

Recent updates

Returns On Capital At RadNet (NASDAQ:RDNT) Have Stalled

RadNet: Qualified Growth Route, Still Undervalued

Price target increased by 7.2% to US$57.17

Is There Now An Opportunity In RadNet, Inc. (NASDAQ:RDNT)?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 23% overvalued after recent price rise

RadNet, Inc., Annual General Meeting, Jun 12, 2024

Price target increased by 7.0% to US$53.33

Are RadNet, Inc. (NASDAQ:RDNT) Investors Paying Above The Intrinsic Value?

Now 21% overvalued after recent price rise

RadNet, Inc. has completed a Follow-on Equity Offering in the amount of $200.2 million.

Consensus EPS estimates increase by 12%

RadNet, Inc.'s (NASDAQ:RDNT) 26% Price Boost Is Out Of Tune With Revenues

Price target increased by 12% to US$45.80

Now 21% overvalued after recent price rise

Full year 2023 earnings: EPS misses analyst expectations

Why RadNet, Inc. (NASDAQ:RDNT) Could Be Worth Watching

RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation

Getting In Cheap On RadNet, Inc. (NASDAQ:RDNT) Might Be Difficult

Insider recently sold US$354k worth of stock

Insider notifies of intention to sell stock

RadNet, Inc. Launches a Pilot Inside Walmart of its New MammogramNow™ Offering

We Think RadNet (NASDAQ:RDNT) Can Stay On Top Of Its Debt

RadNet, Inc. Unveils DeepHealth, a Pioneering AI-Powered Health Informatics Portfolio

RadNet, Inc. Unveils DeepHealth, a Pioneering AI-Powered Health Informatics Portfolio

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

RadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital Effectively

New major risk - Financial position

RadNet, Inc. Appoints Dr. Gregory Sorensen as Executive Vice President and Chief Science Officer

RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt

Radnet, Inc. Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

RadNet, Inc. Announces Appointment of Executives

Consensus EPS estimates upgraded to US$0.10 loss

RadNet, Inc. has completed a Follow-on Equity Offering in the amount of $225.35625 million.

President & COO of Western Operations recently sold US$1.4m worth of stock

RadNet, Inc. Announces Ruth V. Wilson Did Not to Stand for Re-Election to the Board of Directors

President & COO of Western Operations exercised options to buy US$1.5m worth of stock.

RadNet, Inc., Annual General Meeting, Jun 07, 2023

Board Member recently sold US$138k worth of stock

RadNet, Inc. Revises Earnings Guidance for the Year 2023

Price target increased by 7.8% to US$34.50

We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt

President & COO of Eastern Operations recently sold US$230k worth of stock

Insider recently sold US$443k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

RadNet (NASDAQ:RDNT) Will Want To Turn Around Its Return Trends

Radiology Imaging Associates Launches the Enhanced Breast Cancer Detection Program, Providing Women A New State-Of-The-Art Solution Powered by Artificial Intelligence

President & COO of Western Operations recently sold US$97k worth of stock

RadNet (NASDAQ:RDNT) Has A Somewhat Strained Balance Sheet

An Intrinsic Calculation For RadNet, Inc. (NASDAQ:RDNT) Suggests It's 41% Undervalued

Consensus forecasts updated

Third quarter 2022 earnings: EPS misses analyst expectations

RadNet, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment deteriorated over the past week

RadNet, Inc. (NasdaqGM:RDNT) acquired 75% stake in Heart & Lung Imaging Limited.

RadNet JV acquires Montclair Radiology's outpatient radiology assets

Some Investors May Be Worried About RadNet's (NASDAQ:RDNT) Returns On Capital

Price target decreased to US$32.25

Investor sentiment improved over the past week

RadNet Presents With The Idiosyncratic Risk Premia To Deliver Risk-Adjusted Alpha

Investor sentiment improved over the past week

Here's Why RadNet (NASDAQ:RDNT) Has A Meaningful Debt Burden

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

RadNet, Inc. Updates Earnings Guidance for 2022

RadNet Non-GAAP EPS of $0.15 beats by $0.06, revenue of $354.1M beats by $5.16M;reaffirms FY guidance

RadNet (NASDAQ:RDNT) Is Reinvesting At Lower Rates Of Return

Is It Time To Consider Buying RadNet, Inc. (NASDAQ:RDNT)?

President & COO of Western Operations recently sold US$205k worth of stock